MD (1992-1996) Tuft’s University School of Medicine, Boston, MA.
BA Chemistry (1988-1992) University of Vermont, Burlington, VT. Medical Education and Interprofessional Education
Th2 Mediated Airway Inflammation:
• In Cystic Fibrosis
• In Asthma
• Regulators of mucus production
Novel antimicrobial therapies
Microbial interactions in the airway
2002-Present - Director, Adult Cystic Fibrosis Center, University of Vermont Medical Center, Burlington, VT
2016-2017 - Teaching Academy Faculty Associate, University of Vermont, Burlington, VT
2010-Present - Professor of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT
2008-2010 - Associate Professor, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Vermont, Burlington VT
2002-2008 - Assistant Professor, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Vermont, Burlington, VT
Teneback C, Scanlon T, Wargo M, Bement J, Griswold K, Leclair LW. Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrobial Agents and Chemotherapy 2013, 57(11): 5559
Griswold KE, Bement JL, Teneback CC, Scanlon T, Wargo MJ, Leclair LW. Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infections. Bioengineered 2014 Feb 26; 5(2).
Zuckerman JB, Clock SA, Prato BS, McDevitt JJ, Zhou JJ, Leclair LW, Lucas FL, Saiman L. Air contamination with bacteria in cystic fibrosis clinics: implications for prevention strategies. Am J Respir Crit Care Med, 2015 Mar 1; 191(5): 598-601